• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$22.54 -$0.12 (-0.53%)

REAL-TIME: Last trade at

Acorda Therapeutics, Inc.

NASDAQ:ACOR

Goldman Sachs Starts Acorda Therapeutics, Inc. (ACOR) at Sell

Acorda Therapeutics initiated with a Sell at Goldman

Acorda Therapeutics to FDA: What Deadlines?

2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.

U.S. FDA identifies violations of section 505(k) at Acorda Therapeutics

For Acorda Therapeutics, disaster recovery protects vital enterprise assets

Acorda Therapeutics Reports First Quarter 2012 Financial Results

Acorda Therapeutics (ACOR) Tops Q1 EPS by 18c

Acorda Therapeutics sees ZANAFLEX, ex-U.S. FAMPYRA royalty rev at least $25M

Acorda Therapeutics reports Q1 EPS 36c ex-items, consensus 18c

Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Second Consecutive Year

Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Second Consecutive Year

Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2012 Financial Results on May 3, 2012

Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2012 Financial Results on May 3, 2012

Acorda Therapeutics' AMPYRA for multiple sclerosis shows positive Phase 3 result

Acorda Therapeutics to host research and development meeting

Acorda Therapeutics Named One of the 100 Most Trustworthy Companies by Forbes

Acorda Therapeutics Named One of the 100 Most Trustworthy Companies by Forbes

Acorda Therapeutics to Provide Pipeline Update at Upcoming R&D Day

Acorda Therapeutics to Provide Pipeline Update at Upcoming R&D Day

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra® (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis

Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment with Ampyra® (Dalfampridine) of Walking Problems in Patients with Multiple Sclerosis

House Science, Space and Technology Committee to hold a hearing

Acorda Therapeutics coverage resumed with a Buy at Stifel Nicolaus

Institute for International Research to host a summit

Acorda Therapeutics has a conference call hosted by JP Morgan

Acorda Therapeutics to Present at the Cowen & Company 32nd Annual Health Care Conference

Summer Street's healthcare analyst research team hosts a dinner meeting

Acorda Therapeutics to Present at 2012 RBC Capital Markets' Global Healthcare Conference

Acorda Therapeutics to Present at 2012 RBC Capital Markets' Global Healthcare Conference

Top Analyst Upgrades & Downgrades (ACOR, MT, BBBY, CHK, CLF, CMCSA, DELL, EMN, EPD, LEAP, PBR, RL, VLO, WYNN, ZNGA)

Citi Downgrades Acorda Therapeutics, Inc. (ACOR) to Neutral, Raises Price Target to $29

Acorda Therapeutics downgraded to Neutral from Buy at Citigroup

Acorda Therapeutics sees R&D expense for FY12 $50-$60M

Acorda Therapeutics (ACOR) Beats Q4 EPS Expectations; Revs Heavy

Acorda Therapeutics sees FY12 Ampyra net revenue $255M-$275M

Acorda Therapeutics expects to be cash flow positive in 2012

Acorda Therapeutics reports adjusted Q4 EPS 45c vs. consensus 18c

Leerink's biotech analysts to hold an analyst/industry conference call

See More Articles...